Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDL Aims To Acquire New Royalty Assets Before Current Licenses Expire

This article was originally published in The Pink Sheet Daily

Executive Summary

PDL BioPharma has been preparing for the expiry of key patents by making a few hires and reconfiguring its business, with plans to use remaining cash either to purchase new royalty bearing assets or, failing that, to wind up the business.

You may also be interested in...



Can Isis Remain A Platform Company?

With a bulging pipeline, piles of cash, and Big Pharma partners knocking on its doors, Isis believes it is under no pressure to sell its own products. But several factors – including outside pressures and issues intrinsic to Isis’ platform model – are coming into play that may hasten its evolution into an integrated biopharma. And for the first time, Isis management appears open to the possibility.

Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…

Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.

Facet Says Yes To Abbott's $720 Million Buyout Offer

The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel